NCT07019181View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Esophagus Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

DRUG

albumin-bound paclitaxel

albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks

DRUG

Nedaplatin

Nedaplatin 80mg/m2，day 1 of every 3 weeks

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER